Skip to main content
Log in

Application of Allometric Scaling and Salisbury Rule for the Prediction of Antimalarial Drugs for First-in-Pediatric Dose Selection

  • Original Research Article
  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background

In pediatric drug development, the selection of first-in-pediatric dose is of immense importance. Generally, the pharmacokinetic information and a safe and efficacious dose of a drug in adults are already known and this information can then be used to select first-in-pediatric dose. The objective of this study was to predict the pediatric dose of antimalarial drugs and compare the predicted dose with the recommended dose.

Methods

In this study, two simple methods to project a first-in-pediatric dose to initiate a clinical trial for antimalarial drugs were evaluated. These two methods were Salisbury Rule and allometric scaling. The predicted doses of antimalarial drugs by the two methods were compared with the observed doses recommended by the World Health Organization (WHO) or the US Food and Drug Administration (FDA).

Results

In this study, 15 antimalarial drugs with 88 observations (different body weight groups) were evaluated. From allometric scaling, all 88 observations were within 0.5–1.5-fold and 0.7–1.3-fold prediction error. From Salisbury Rule, all 88 observations were within 0.5–1.5-fold and 86 observations were within 0.7–1.3-fold prediction error.

Conclusions

The proposed methods are simple and quite accurate in their predictive power. These methods can be developed on a spreadsheet or a calculator in a very short period of time and are applicable to first-in-pediatric clinical trials or even in a clinical setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Talapharmacokineticso J, Skrlec I, Alebi T, Juki M, Vcev A. Malaria: the past and the present. Microorganisms. 2019;7:179.

    Article  Google Scholar 

  2. Mahmood I. Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings. Clin Pharmacokinet. 2014;53:327–46.

    Article  CAS  PubMed  Google Scholar 

  3. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–67.

    Article  CAS  PubMed  Google Scholar 

  4. Green DJ, Zineh I, Burckart GJ. Pediatric drug development: outlook for science-based innovation. Clin Pharmacol Ther. 2018;103:376–8.

    Article  PubMed  Google Scholar 

  5. Abernethy DR, Burckart GJ. Pediatric dose selection. Clin Pharmacol Ther. 2010;87:270–1.

    Article  CAS  PubMed  Google Scholar 

  6. Elias GP, Antoniali C, Mariano RC. Comparative study of rules employed for calculation of pediatric drug dosage. J Appl Oral Sci. 2005;13:114–9.

    Article  PubMed  Google Scholar 

  7. Mahmood I. Dose selection in children. In: Pharmacokinetic allometric scaling in pediatric drug development. Rockville: Pine House Publishers; 2013. p. 151–60.

    Google Scholar 

  8. Lack JA, Stuart-Taylor ME. Calculation of drug dosage and body surface area of children. Br J Anaesth. 1997;78:601–5.

    Article  CAS  PubMed  Google Scholar 

  9. Munzenberger PJ, McKercher P. Pediatric dosing-the pharmacist’s dilemma. Contemp Pharm Pract. 1980;3:11–4.

    CAS  PubMed  Google Scholar 

  10. Mahmood I. A comparison of different methods for the first-in-pediatric dose selection. J Clin Transl Res. 2022;8:369–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Mahmood I. A simple method for the prediction of therapeutic proteins (monoclonal and polyclonal antibodies and non-antibody proteins) for first-in-pediatric dose selection: application of salisbury rule. Antibodies. 2022;11(66):2–12.

    Google Scholar 

  12. WHO. Guidelines for the treatment of malaria. 3rd ed. World Health Organization; 2015.

    Google Scholar 

  13. FDA package insert of FANSIDAR (sulfadoxine and pyrimethamine), 1996.

  14. FDA package insert of COARTEM (artemether/lumefantrine), 2009.

  15. FDA package insert of MALARONE(atovaquone and proguanil hydrochloride), 2008.

  16. FDA package insert of LARIAM (mefloquine hydrochloride), 2003.

  17. FDA package insert of PLAQUENIL (HYDROXYCHLOROQUINE SULFATE), 2015.

  18. FDA package insert of CHLOROQUINE PHOSPHATE, 2009.

  19. Mahmood I. Dose selection in children: allometry and other methods. In: Pediatric pharmacology and pharmacokinetics. Rockville: Pine House Publishers; 2008. p. 184–216.

    Google Scholar 

  20. Mansoor N, Ahmad T, Alam Khan R, Sharib SM, Mahmood I. Prediction of clearance and dose of midazolam in preterm and term neonates: a comparative study between allometric scaling and physiologically based pharmacokinetic modeling. Am J Ther. 2019;26:e32–7.

    Article  PubMed  Google Scholar 

  21. Senarathna SM, Batty KT. Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing. Antimicrob Agents Chemother. 2014;58:6068–78.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Mahmood I, Cheng A, Brauer E, Humeniuk R. Prediction of antimalarial drug clearance in children: a comparison of three different interspecies scaling methods. Eur J Drug Metab Pharmacokinet. 2016;41:767–75.

    Article  CAS  PubMed  Google Scholar 

  23. Deyme L, Benzekry S, Ciccolini J. Mechanistic models for hematological toxicities: Small is beautiful. CPT Pharmacomet Syst Pharmacol. 2021;10:396–8.

    Article  CAS  Google Scholar 

  24. Box GEP. Science and statistics. J Am Stat Assoc. 1976;71:791–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Iftekhar Mahmood.

Ethics declarations

Funding

No funds were sought from any private or government source.

Conflict of interest

The author has no conflict of interest.

Ethical approval

Not applicable.

Availability of data and material

Data were taken from the literature and references are provided in the manuscript.

Code availability

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Author contribution

This is a single author article. IM conceived the research project, collected and analyzed the data, and wrote the manuscript.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mahmood, I. Application of Allometric Scaling and Salisbury Rule for the Prediction of Antimalarial Drugs for First-in-Pediatric Dose Selection. Eur J Drug Metab Pharmacokinet 48, 587–594 (2023). https://doi.org/10.1007/s13318-023-00848-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13318-023-00848-2

Navigation